Biopharmaceutical firms are pivoting RNA interference technology from rare genetic disorders to high-prevalence cardiovascular conditions. Recent Phase III trial data indicates sustained suppression of target liver proteins involved in cholesterol synthesis.
Adherence and Efficacy Metrics
Infrequent dosing schedules present a structural advantage over daily oral therapeutics. Health systems report improved long-term patient compliance, reducing secondary hospital admissions for cardiovascular events.